$30 million to University of Michigan startup blurs corporate-academic borders
Filed in archive Institutions by george elvin on August 08, 2006

NanoBio Corporation develops therapies and vaccines against infections ranging from cold sores to nail fungus
and influenza using a novel nanoemulsion technology developed at U-M."There is great promise for vaccines based on this technology because they can be administered without the use of needles or refrigeration," Professor Baker said.
His initial research took place at U-M with funding from the U.S. Department of Defense's Defense Advanced Research Programs Agency (DARPA). The vaccine work was funded by grants from the National Institute for Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation.
U-M has licensed the technology exclusively to NanoBio. In addition to holding an equity stake in the company, the University would receive royalties should the products achieve commercial success.
As this $30 million investment shows, nanotech is blurring the line between the corporate and academic worlds. Can a university be objective when it receives product royalties? Does this kind of reward sway what researchers choose to study? Where does the corporate connection leave the students? We'll see. (photo Michigan Nanotechnology Institute for Medicine and Biological Sciences)
Permalink: $30 million to University of Michigan startup blurs corporate-academic borders
Tags:
nanotechnology nanotech nano investment academic corporate university university+michigan
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/31382












